Viruses cause approximately 15% of human cancers. A viral etiology to a human cancer can have substantive consequences on its treatment and prevention. For example, many virally-caused human cancers express virally encoded products, which are potential targets for anti-viral, tumor-specific therapies. In addition unique sets of cellular genes and pathways contribute to virally-associated cancers, many of which are currently being pursued as targets for anti-cancer therapies. This program project grant (PPG), now In its 35th year of continual funding, has two objectives: to use molecular biology and genetics to elucidate the life cycles of and transformation by human tumor viruses and to translate this understanding into the identification of targets for specific anti-viral, ant-tumor therapies. The PPG has seven senior investigators who share these research goals in studying human tumor viruses in three different virus families: papillomaviruses, hepadnaviruses and herpesviruses. Together, these three families of viruses cause the vast majority of virally-associated human cancers. Our PPG evolved over the current funding period to be composed of projects in which two or more investigators work together on a common theme in human tumor virology. Cross-fertilization of ideas and expertise between projects is fostered by having investigators work on multiple projects. This interactive and collaborative organization has been highly fruitful over th current funding period in several regards. Firstly, each project has been highly productive. Secondly, innovative new ideas and approaches have arisen many of which are now being used across multiple projects. Thirdly, the collaborative environment created by this PPG has spawned new interactions that are bringing additional expertise to the PPG. Most important of these interactions have been collaborations between Drs. Shannon Kenney and Rob Kalejta that have led to our including Dr. Kalejta as a new co-leader on two existing projects. The specific themes of this PPG are: 1) to identify and characterize cellular genes that drive human papillomavirus-associated cancer and modulate viral infection;2) to define the role of the hepatitis B virus core protein in multiple steps of the viral life cycle;3) to study the replicatin and inheritance of herpesviral genomes in relevant cell types using novel approaches for live cell imaging;4) to characterize cellular and viral factors that regulate the switch from the laten to lytic viral state of Epstein Barr virus (EBV);and 5) to define drivers of EBV-associated carcinogenesis and develop novel approaches for treating these cancers and diseases caused by herpesviruses.

Public Health Relevance

Viruses contribute to at least 20 different human cancers, representing approximately 15% of all human cancers. Understanding how the biology of these human tumor viruses and how they cause cancer will provide new approaches for preventing and treating the associated cancers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA022443-37
Application #
8675198
Study Section
Special Emphasis Panel (ZCA1-RPRB-2 (J1))
Program Officer
Daschner, Phillip J
Project Start
1997-02-01
Project End
2018-04-30
Budget Start
2014-05-01
Budget End
2015-04-30
Support Year
37
Fiscal Year
2014
Total Cost
$2,001,744
Indirect Cost
$661,266
Name
University of Wisconsin Madison
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Zumwalde, Nicholas A; Sharma, Akshat; Xu, Xuequn et al. (2017) Adoptively transferred V?9V?2 T cells show potent antitumor effects in a preclinical B cell lymphomagenesis model. JCI Insight 2:
Ma, Shi-Dong; Tsai, Ming-Han; Romero-Masters, James C et al. (2017) Latent Membrane Protein 1 (LMP1) and LMP2A Collaborate To Promote Epstein-Barr Virus-Induced B Cell Lymphomas in a Cord Blood-Humanized Mouse Model but Are Not Essential. J Virol 91:
Bilger, Andrea; Plowshay, Julie; Ma, Shidong et al. (2017) Leflunomide/teriflunomide inhibit Epstein-Barr virus (EBV)- induced lymphoproliferative disease and lytic viral replication. Oncotarget 8:44266-44280
Yang, Ya-Chun; Liem, Amy; Lambert, Paul F et al. (2017) Dissecting the regulation of EBV's BART miRNAs in carcinomas. Virology 505:148-154
Iwahori, Satoko; UmaƱa, Angie C; VanDeusen, Halena R et al. (2017) Human cytomegalovirus-encoded viral cyclin-dependent kinase (v-CDK) UL97 phosphorylates and inactivates the retinoblastoma protein-related p107 and p130 proteins. J Biol Chem 292:6583-6599
Wille, Coral K; Li, Yangguang; Rui, Lixin et al. (2017) Restricted TET2 Expression in Germinal Center Type B Cells Promotes Stringent Epstein-Barr Virus Latency. J Virol 91:
Chandra, Janin; Kuo, Paula T Y; Hahn, Anne M et al. (2017) Batf3 selectively determines acquisition of CD8+ dendritic cell phenotype and function. Immunol Cell Biol 95:215-223
Pocock, Ginger M; Zimdars, Laraine L; Yuan, Ming et al. (2017) Diverse activities of viral cis-acting RNA regulatory elements revealed using multicolor, long-term, single-cell imaging. Mol Biol Cell 28:476-487
Nowak, Karolin; Linzner, Daniela; Thrasher, Adrian J et al. (2017) Absence of ?-Chain in Keratinocytes Alters Chemokine Secretion, Resulting in Reduced Immune Cell Recruitment. J Invest Dermatol 137:2120-2130
Uberoi, Aayushi; Lambert, Paul F (2017) Rodent Papillomaviruses. Viruses 9:

Showing the most recent 10 out of 420 publications